GIANT BIOGENE's collagen facial injection product has received the registration certificate from the drug regulatory authority
GIANT BIOGENE (02367.HK) announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE, has today received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its recombinant type I α1 collagen freeze-dried fiber product. This product, which uses recombinant collagen as the main ingredient, is intended for facial dermal tissue filling to correct dynamic wrinkles in the forehead, including glabellar lines, forehead lines, and crow's feet.
The company stated that this product is China's first recombinant type I natural sequence collagen facial injectable product, officially approved through a joint review by the device and drug regulatory authorities
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments